ZYCORTAL Suspension contains desoxycorticosterone pivalate which is a mineralocorticoid hormone indicated for use as replacement therapy for mineralocorticoid deficiency in dogs with primary hypoadrenocorticism (Addison’s disease). ZYCORTAL Suspension was formulated and approved specifically for subcutaneous use. The desoxycorticosterone pivalate (DOCP) in ZYCORTAL Suspension is a pure mineralocorticoid hormone that regulates electrolytes and water balance, which are impaired in cases of mineralocorticoid deficiency in Addison’s disease. only. Dogs with combined glucocorticoid and mineralocorticoid deficiency should also be treated with prednisone or prednisolone at an initial dosage of 0.2-0.4 mg/kg/day (0.1-0.2 mg/lb/day). Use ZYCORTAL Suspension with caution in dogs with congestive heart disease, edema, severe renal disease or primary hepatic failure. Refer to the prescribing information for complete details visit www.dechra-us.com\zycortal Released March 2016.